March 18, 2021DS Biopharma and Nuvothera Enter Option and License Agreement for EPADILIN®• Nuvothera acquires option to licence rights to develop and commercialise DS Biopharma’s EPADILIN® in the US • DS Biopharma becomes an investor in Nuvothera and […]
